# US 2016/0354458 A1 · Tilapia lake virus vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354458 A1
- Document ID: US20160354458A1
- Status: Published application
- Kind: A1
- Application number: 15/117,833
- Filed: 2015-02-11
- Published: 2016-12-08
- Earliest claimed: 2014-02-13
- Assignees: The State of Israel, Ministry of Agriculture & Rur al Development, Kimron Veterinary Institute; Ramot at Tel-Aviv University Ltd.
- Applicants: The State of Israel, Ministry of Agriculture & Rural Development, Kimron Veterinary Institute; Ramot At Tel-Aviv University Ltd.
- Inventors: Eran Bacharach; Avi Eldar
- Web page: https://patentgrep.com/patent/US20160354458A1

## CPC

- A61K 39/12: Viral antigens
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2760/00: ssRNA viruses negative-sense
- C12N 2760/00011: Details
- C12N 2760/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.

## Claims

### Claim 1

A vaccine composition comprising an attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV).

### Claim 2 (depends on 1)

The vaccine composition according to claim 1, wherein the attenuated strain is obtained by sequential passages in tissue culture.

### Claim 3 (depends on 1)

The vaccine composition according to claim 1, wherein the attenuated strain is obtained by passages in a host.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The vaccine composition according to claim 1, further comprising an acceptable carrier, diluent or adjuvant.

### Claim 8 (depends on 1)

The vaccine composition according to claim 1, wherein the tilapia fish is a member of the Cichlidae family.

### Claim 9 (depends on 8)

The vaccine composition according to claim 8, wherein the member of the Cichlidae family is selected from the species Sarotherodon, Tilapia and Oreochromis, or any hybrid thereof.

### Claim 10

An isolated TiLV deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) of Institut Pasteur (France), under the depository accession number CNCM I-4817.

### Claim 11

A method for immunizing tilapia fish against TiLV infection comprising administrating to said fish a vaccine composition comprising an attenuated strain of TiLV in an amount sufficient to induce immunity to subsequent infection by TiLV.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the vaccine composition is administered to the fish orally via food.

### Claim 13 (depends on 12)

The method of claim 12, wherein the vaccine composition is coated by protective coating.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the vaccine composition is administered to said fish by injection.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the vaccine composition is administered to said fish by dissolving or immersing the vaccine composition in the body of water.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the immunity is induced in said fish by cohabitation.

### Claim 17 (depends on 11)

The method according to claim 11, wherein the vaccine composition is administered to said fish by spraying the composition on fish which are temporarily removed from the body of water.

### Claim 18 (depends on 11)

The method according to claim 11, further comprising maintaining the immunized fish in temperature of 31° C. for 3-5 days, followed by transfer to 22° C. for at least 25 days.

### Claim 19 (depends on 11)

The method according to claim 11, wherein the attenuated strain is obtained by sequential passages in tissue culture.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 11)

The method according to claim 11, wherein the attenuated strain is obtained by passages in a host.

### Claim 23 (depends on 11)

The method according to claim 11, wherein the vaccine composition further comprises an acceptable carrier, diluent or adjuvant.

### Claim 24 (depends on 11)

The method according to claim 11, wherein the tilapia fish is a member of the Cichlidae family.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the member of the Cichlidae family is selected from the species Sarotherodon, Tilapia and Oreochromis, or hybrid thereof.

### Claim 26

(canceled)
